Today, the FDA approved Xenoport’s (NASDAQ:XNPT) and GlaxoSmithKline’s (NYSE:GSK) Horizant (gabapentin enacarbil) for the treatment of Restless Leg Syndrome (‘RLS’). EfficacyThe efficacy of Horizant in the treatment of patients with moderate-to-severe primary.
After yesterday’s 13-0 FDA advisory committee vote of confidence in Optimer’s Clostridium difficile infection (CDI) drug, now known as Dificid (fidaxomicin), the company has moved quickly to secure a co-promotion.
Today, the FDA’s independent expert panel voted unanimously 13-0 that Optimer’s drug, fidaxomicin, is safe and effective for the treatment of Clostridium difficile infection (CDI). The panel was split six.
First off, Cubist has just settled with Teva over their patent litigation that will prevent Teva from entering the market until 2018. More details on that later. I got a.
POZEN recently announced it had struck a licensing deal with Cilag GmbH, a division of Johnson & Johnson to develop and commercialize its migraine treatment, MT-400 in Brazil, Colombia, Ecuador.
The date is fast approaching for Cubist’s face-off with Teva in its court battle over Teva’s Paragraph IV filing against Cubicin patents. A judge is set to hear their case.
Within a week, Xenoport (NASDAQ:XNPT) and partner GlaxoSmithKline (NYSE:GSK) should receive feedback from the FDA regarding the NDA for Horizant, a gabapentin pro-drug for the treatment of Restless Leg Syndrome.
During the past week, Depomed (DEPO) announced two significant business development updates. On March 15th, Depomed granted non-exclusive rights for its proprietary extended-release metformin patents, this time, to Boehringer Ingelheim..
Today, Seattle Genetics announced a partnership with Abbott to develop a drug against a single target using their antibody-drug-conjugate (ADC) technology. Abbott will pay $8 million upfront and up to.
HCV is a highly lucrative space to be in right now- witness the huge spike in Pharmasset’s share price merely on the presentation of tantalizing Phase 1 data. An entirely.
Pozen is a small, unconventional drug developer with two approved drugs and another expected to soon follow. The company specializes in devising novel formulations of existing drugs, allowing for an.
Exelixis has skyrocked over 300% from its August lows to its current price of about $12 on positive news for its lead compound, cabozantinib in prostate cancer, giving it a.
I discussed the merits of these company’s in a short post back in June last year (Calistoga Pharmaceuticals and Plexxikon- Two Biotechs to Keep an Eye On). I had hoped.
This is the kind of company I like- cash rich and undervalued. Cubist Pharmaceuticals had $910 million in cash at the end of 2010 and a current market cap of.
In 2009, Purdue Pharma’s Oxycontin, an opioid pain reliever, reached annual sales that topped $3 billion. That represents a 300% increase over annual sales in 2001. Clearly, prescriptions for opioid.
Earlier this month, Bionovo (NASDAQ:BNVI), a development-stage pharmaceutical company, announced a plan of action for its lead product candidate, Menerba, an oral, botanical, drug candidate for the treatment of menopausal.
Vivus (NASDAQ:VVUS), a specialty pharmaceutical company, has faced some setbacks with its drug candidate, Qnexa, an investigational treatment for obesity, obstructive sleep apnea and diabetes. In October 2010, Vivus received.
It almost seems counterintuitive that majority shareholders of Depomed (DEPO) have been adding shares after the FDA approval of Gralise, a once-daily treatment for post-herpetic neuralgia. One might expect that.